FDA Approved Gilteritinib May Increase Cure Rates for Mutated FLT3 Genes in AML
The oral inhibitor drug gilteritinib (XOSPATA®) was recently approved by the FDA based on interim results of the clinical trial ADMIRAL, according to an article in EurekAlert for Science News. A…